Oncocidia is the result of 15 years research programme conducted by the team of Professor Yicheng Ni, Head of the Theragnostic Laboratory at KU Leuven University, Belgium.
Along with its inventor, Oncocidia has been the subject of prestigious scientific awards and honours. The proposed treatment has demonstrated efficacy in animals, with the results published extensively.
Oncocidia Limited was set up in 2016 to take this treatment into clinical trials, with funding provided by its Chairman, Charles Jonscher, and London based technology commercialization company CetroMed Limited.
A Phase I clinical trial is expected to commence in late 2019, subject to obtaining all regulatory and other approvals.
Oncocidia in the context of current cancer research
Cancer drug development, historically based on the three pillars of surgery, chemotherapy and radiotherapy, is now benefiting from the application of highly advanced science - especially immuno-oncology, which seeks to fight cancers by stimulating the body’s natural immune system.
By contrast Oncocidia is based on relatively straightforward and well-understood principles: a necrotic mass is created in the tumour and a radioactive dose locates the necrosis in the tumour and irradiates what remains of it.